180 related articles for article (PubMed ID: 8269587)
1. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1993; 33(1):36-42. PubMed ID: 8269587
[TBL] [Abstract][Full Text] [Related]
2. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and pharmacokinetics of oral and intravenous ifosfamide.
Kurowski V; Cerny T; Küpfer A; Wagner T
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S148-53. PubMed ID: 1795004
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
5. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Kerbusch T; Mathôt RA; Keizer HJ; Kaijser GP; Schellens JH; Beijnen JH
Drug Metab Dispos; 2001 Jul; 29(7):967-75. PubMed ID: 11408362
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
Kerbusch T; vanPutten JW; Groen HJ; Huitema AD; Mathĵt RA; Beijnen JH
Cancer Chemother Pharmacol; 2001 Jul; 48(1):53-61. PubMed ID: 11488525
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide.
Brüggemann SK; Kisro J; Wagner T
Cancer Res; 1997 Jul; 57(13):2676-80. PubMed ID: 9205076
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
Kerbusch T; Mathĵt RA; Keizer HJ; Ouwerkerk J; Rodenhuis S; Schellens JH; Beijnen JH
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):467-77. PubMed ID: 11699611
[TBL] [Abstract][Full Text] [Related]
10. Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma.
Kaijser GP; Beijnen JH; Jeunink EL; Bult A; Keizer HJ; de Kraker J; Underberg WJ
J Chromatogr; 1993 May; 614(2):253-9. PubMed ID: 8314937
[TBL] [Abstract][Full Text] [Related]
11. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
[TBL] [Abstract][Full Text] [Related]
13. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma.
McNiel NO; Morgan LR
Int J Clin Pharmacol Ther Toxicol; 1981 Nov; 19(11):490-3. PubMed ID: 7298241
[TBL] [Abstract][Full Text] [Related]
14. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients.
Brüggemann SK; Pfäffle S; Peters SO; Wagner T
Drug Metab Dispos; 2007 Oct; 35(10):1721-4. PubMed ID: 17600085
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of ifosfamide and some metabolites in children.
Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
[TBL] [Abstract][Full Text] [Related]
16. Determination of 4-hydroxyifosfamide concomitantly with ifosfamide and its dechloroethylated metabolites using gas chromatography and a nitrogen phosphorus-selective detector.
Gourmel B; Granvil CP; Denis SL; Wainer IW; Bousquet B
J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(1):3-15. PubMed ID: 10517217
[TBL] [Abstract][Full Text] [Related]
17. Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity.
Brueggemann SK; Schlenke P; Klich S; Deeken M; Peters SO; Wagner T
Biochem Pharmacol; 2002 Apr; 63(7):1337-41. PubMed ID: 11960610
[TBL] [Abstract][Full Text] [Related]
18. New insights into the clinical pharmacokinetics of trofosfamide.
Brinker A; Kisro J; Letsch C; Brüggemann SK; Wagner T
Int J Clin Pharmacol Ther; 2002 Aug; 40(8):376-81. PubMed ID: 12467306
[TBL] [Abstract][Full Text] [Related]
19. Gas chromatographic determination of 2- and 3-dechloroethylifosfamide in plasma and urine.
Kaijser GP; Beijnen JH; Bult A; Wiese G; de Kraker J; Keizer HJ; Underberg WJ
J Chromatogr; 1992 Dec; 583(2):175-82. PubMed ID: 1478981
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability of ifosfamide in patients with bronchial carcinoma.
Cerny T; Margison JM; Thatcher N; Wilkinson PM
Cancer Chemother Pharmacol; 1986; 18(3):261-4. PubMed ID: 3802382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
